Therapeutic strategies to target the CXCR-1/CXCR-2 axis or combination with immunotherapy have been proposed to improve antitumor efficacy in pancreatic cancer, metastatic melanoma, and metastatic colorectal carcinoma (35, 36). Here, CXCR1 is linked to familial pancreatic carcinoma.